Exacerbation of allergic inflammation in mice exposed to diesel exhaust particles prior to viral infection

Ilona Jaspers*1,2, Patricia A Sheridan3, Wenli Zhang2, Luisa E Brighton2, Kelly D Chason, Xiaoyang Hua2,4 and Stephen L Tilley2,4

Address: 1Department of Pediatrics, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA, 2Center for Environmental Medicine, Asthma, and Lung Biology, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA, 3Department of Nutrition, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA and 4Department of Medicine, Division of Pulmonary and Critical Care Medicine, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA

Email: Ilona Jaspers* - Ilona_jaspers@med.unc.edu; Patricia A Sheridan - patricia_sheridan@med.unc.edu; Wenli Zhang - wenli_zhang@med.unc.edu; Luisa E Brighton - mek@med.unc.edu; Kelly D Chason - chason@email.unc.edu; Xiaoyang Hua - xiaoyang_hua@med.unc.edu; Stephen L Tilley - stephen_tilley@med.unc.edu

* Corresponding author

Abstract

Background: Viral infections and exposure to oxidant air pollutants are two of the most important inducers of asthma exacerbation. Our previous studies have demonstrated that exposure to diesel exhaust increases the susceptibility to influenza virus infections both in epithelial cells in vitro and in mice in vivo. Therefore, we examined whether in the setting of allergic asthma, exposure to oxidant air pollutants enhances the susceptibility to respiratory virus infections, which in turn leads to increased virus-induced exacerbation of asthma. Ovalbumin-sensitized (OVA) male C57BL/6 mice were instilled with diesel exhaust particles (DEP) or saline and 24 hours later infected with influenza A/PR/8. Animals were sacrificed 24 hours post-infection and analyzed for markers of lung injury, allergic inflammation, and pro-inflammatory cytokine production.

Results: Exposure to DEP or infection with influenza alone had no significant effects on markers of injury or allergic inflammation. However, OVA-sensitized mice that were exposed to DEP and subsequently infected with influenza showed increased levels of eosinophils in lung lavage and tissue. In addition Th2-type cytokines, such as IL-4 and IL-13, and markers of eosinophil chemotaxis, such as CCL11 and CCR3, were increased in OVA-sensitized mice exposed to DEP prior to infection with influenza. These mice also showed increased levels of IL-1α, but not IL-10, RANTES, and MCP-1 in lung homogenates.

Conclusion: These data suggest that in the setting of allergic asthma, exposure to diesel exhaust could enhance virus-induced exacerbation of allergic inflammation.

Background

The prevalence of allergic diseases, such as asthma, continues to be on the rise in developed countries. While genetic components most certainly account for some of the susceptibility of developing asthma, the increased prevalence of allergic airway diseases cannot be completely explained on the basis of genetics. A number of extrinsic factors, including nutrition, exposure to environ-
mental pollutants, and lack of exposure to a variety of pathogens during childhood are also suspected to contribute to the susceptibility of developing asthma later on in life as well as the severity of the disease [1]. Moreover, there are a number of triggers that can exacerbate the disease and lead to acute allergic inflammation of the airways. Epidemiologic studies have repeatedly demonstrated that exposure to particulate air pollutants is associated with exacerbation of asthma and increased medication use [2,3]. While there have been a number of very interesting findings regarding potential roles for chronic exposure to diesel exhaust (DE), such as acting as an adjuvant or enhancing the development of allergic airway disease [4-6], it is not yet clear how acute exposure to DE could lead to exacerbation of asthma. In a number of murine models of allergic asthma, exposure to DEP increased airway obstruction and enhanced allergen-dependent and independent airway responsiveness [7-9]. However, human studies examining inflammatory markers in the airways of asthmatics and non-asthmatics have demonstrated that short-term exposure to DE does not worsen pre-existing allergic airway inflammation [10]. It has been suggested that exposure to DE lowers the immune activation threshold for inducing asthmatic symptoms, and therefore increases the susceptibility to exacerbation of the disease [11]. For example, bronchial epithelial cells obtained from asthmatics constitutively expressed higher levels of IL-8, GM-CSF, RANTES, and sICAM and were more sensitive to DEP-induced inflammatory mediator production as compared to non-asthmatic controls [12,13]. In addition, DEP enhanced the activation of T cells obtained from asthmatics, but not from non-asthmatic controls [11].

While exposure to air pollutants such as DE can exacerbate asthma, the majority of clinically documented asthma exacerbations are associated with viral infections [14]. Specifically, rhinovirus (RV) is the most common virus detected in asthmatics during exacerbations, but the spectrum of viruses also includes influenza virus, especially during epidemics [14,15]. Viral respiratory tract infection-induced acute exacerbations of asthma lead to increased health care utilization including hospitalization [16]. In a series of adults hospitalized with asthma, influenza was reported to make up 60% of cases in which a respiratory pathogen was isolated using tissue culture methods [17]. Thus, while not as common as RV in asthma exacerbations, influenza may account for a relatively high proportion of severe cases, and is therefore relevant from clinical and public health perspectives. The mechanisms mediating virus-induced exacerbation of asthma are derived from a number of in vitro models as well as experimental human infections with rhinovirus [18]. In addition, a number of animal models have been developed, including models examining the role of influenza in virus-induced asthma exacerbation [19]. The phenotype of virus-induced aggravation of allergic asthma includes increased eosinophilia, increased Th2-type immune response, and increase airway hyperreactivity [19].

Our previous studies have demonstrated that exposure to DE increases the susceptibility to influenza virus infections both in epithelial cells in vitro and in mice in vivo and that this response is mediated by oxidative stress [20,21]. Recent epidemiologic evidence suggests that personal exposure to oxidant air pollutants increases the severity of virus-induced asthma exacerbations [22]. These observations suggest an additive or synergistic interaction between oxidant air pollution exposure and virus-induced exacerbation of asthma. The study described here investigated whether and how acute exposure to DEP prior to infection with influenza virus affects exacerbation of allergic inflammation in a murine model of asthma. Our results demonstrate that in our model exposure to DEP prior to infection with influenza resulted in significant enhancement of allergic airways inflammation, while either treatment alone did not.

Results

Exposure to DEP prior to infection with influenza increases markers of inflammation and lung injury

C57BL/6 male mice were sensitized and challenged with OVA, then challenged with Influenza (Flu), DEP, or saline as shown in Fig. 1. Histological examination of overall inflammation and infiltration of inflammatory cells was performed, which demonstrated that accumulation of inflammatory cells was greatest in the DEP/Flu group of animals (Fig. 2A). In addition, levels of protein in the BAL fluid (BALF), a marker of edema, were measured. Fig. 2B shows that exposure to DEP prior to infection with influ-

Figure 1
Schematic of experimental protocol, indicating times of OVA challenge, DEP-exposure, and virus infection.
enza significantly increased BALF protein levels. Neither exposure to DEP or infection with influenza alone significantly increased BALF protein.

Exposure to DEP prior to infection with influenza increases the number of lung tissue eosinophils

To further assess eosinophil infiltration into the lung, lung sections were stained using a Carbol Chromotrope to identify eosinophils. Average numbers of tissue eosinophils located around small airways (150–200 μm luminal diameter) and blood vessels (10–50 μm luminal diameter) are shown in Fig. 4A. Similar to eosinophils numbers in BALF, tissue eosinophils were significantly elevated in animals exposed to DEP prior to infection with influenza. Representative images of Carbol Chromotrope stained sections for airways (4B+C) and blood vessels (4D+E) from the DEP/Flu group of animals are shown in Fig. 4B–E.

Effects of exposure to DEP prior to infection with influenza on markers of eosinophils recruitment

Eosinophil recruitment into the lung is controlled by the release of specific chemokines and expression of their respective receptors on the surface of eosinophils. CCR3 is highly expressed on eosinophils in both humans and mice and mediates chemotaxis and recruitment of eosinophils into the lung [23]. CCR3 binds a number of different chemokines, including eotaxin 1, 2, and 3 (CCL 11, 24, and 26 respectively), as well as MCP-2, 3, and 4 (CCL 8, 7, and 13) and RANTES (CCL5) [23], with CCL11 being more specifically involved in eosinophils recruitment into the lung. Fig. 5A shows that expression of CCL11 was significantly elevated in OVA-sensitized mice exposed to DEP prior to infection with influenza. Similarly, expression of CCR3 was significantly enhanced in the DEP/Flu experimental group as shown in Fig. 5B. Interestingly neither exposure to DEP or infection with influenza alone had any significant effect on the expression of CCL11 or CCR3 in OVA-sensitized mice.

Effects of exposure to DEP prior to infection with influenza on inflammatory cytokine expression

Next the effects of DEP prior to infection with influenza in OVA-sensitized mice on the expression of inflammatory cytokines were examined, with a specific focus on TH2 cytokines, including IL-13 and IL-4. Fig. 6A shows that the level of IL-13 in BALF was significantly enhanced in animals exposed to DEP prior to infection with influenza. Exposure to DEP or infection with influenza alone resulted in a small, but not statistically significant enhancement of IL-13. Similarly, Fig. 6B shows that levels
of IL-4 in lung homogenates (BALF IL-4 levels were below the detection limit; data not shown), were significantly enhanced in animals exposed to DEP prior to infection with influenza. Both IL-4 and IL-13 bind to the alpha chain of the IL-4 receptor (IL-4Rα). Fig. 6C shows that expression of IL-4Rα was significantly increased in animals exposed to DEP prior to infection with influenza. Taken together, these data show that in OVA-sensitized mice, exposure to DEP prior to infection with influenza enhanced the expression of the TH2 cytokines IL-4 and IL-13 and their common receptor IL-4Rα. In addition, a number of other cytokines with known roles in either DEP-induced inflammation or influenza-induced responses were examined in lung homogenates. Table 2 summarizes these results and demonstrates that there were no changes in any groups in the levels of IL-10, MCP-1, and RANTES in lung homogenates. However, IL-1α levels were significantly enhanced in OVA-sensitized animals exposed to DEP prior to infection with influenza.

**Effects of DEP and influenza virus infection on OVA-specific antibody levels**

The OVA sensitization and challenge model used here will result in OVA-specific antibody formation. To determine whether exposure to DEP, infection with influenza, or exposure to DEP prior to infection with influenza affected OVA-specific antibody levels, we examined OVA-specific IgG2c, IgE, and IgG1 levels in sera from mice. Table 3 shows that exposure to DEP, infection with influenza, or the combination treatment had no significant effects on OVA-specific IgG2c or IgG1 levels. OVA-specific IgG2c levels were elevated in animals exposed to DEP alone, influenza alone, and DEP prior to infection with influenza as compared to the control group (Sal/Sal), albeit not statistically significant.

**Effects of DEP on influenza viral titers**

Next, we examined whether in OVA-sensitized mice, a single instillation of DEP enhanced influenza viral titers in the lung. Influenza viral titers were measured at the time of characterization of allergic inflammation (18 h post-viral inoculation) by using the TCID₅₀ assay. As shown in Fig 7, a trend towards greater viral titers was seen in the DEP-treated group (P = 0.07), even at this early-time point post-inoculation.

**Discussion**

Respiratory virus infections are by far the greatest risk factor for exacerbation of asthma, especially in children. Considering that concurrent exposures to air pollutants, such as DE, and respiratory viruses are likely, additive or synergistic effects between these exposures in individuals with preexisting allergic airways disease could be of potential public health significance. Although exposure to DE or DEP alone can induce a number of adverse immunological effects including increased inflammatory cytokine production, the effects of DE or DEP have been repeatedly shown to be much greater in conjunction with another immunological stimulus. Our previous work has demonstrated that exposure to DE or DEP increases the susceptibility to influenza virus infections [20,21]. Similarly, a number of studies have demonstrated that exposure to DE or DEP increases sensitization to experimental allergens such as ovalbumin [9,24,25]. Our study was designed to test whether and how virus-induced exacerbation of allergic airway inflammation is affected by exposure to oxidant air pollutants. Specifically, we examined how exposure to DEP prior to infection with influenza virus modifies markers of allergic inflammation in a murine model of asthma. Our data shown here demonstrate that in mice with allergic airway disease, exposure to DEP prior to infection with influenza increases the number of lung eosinophils, markers of eosinophils chemotaxis, and TH2 cytokine levels, while exposure to DEP or infection with influenza alone did not. These data indicate that exposure to DEP could potentially sensitize the lung to virus-induced exacerbation of allergic airways inflammation.

**Compelling epidemiologic evidence that exposure to oxidant air pollutants can enhance the severity of virus-induced asthma exacerbations comes from a study con-**
ducted by Chauhan et al. [22]. This study demonstrated that exposure to the oxidant air pollutant NO₂ the week before the onset of a respiratory virus infection significantly increased the severity of the resulting asthma exacerbation in a cohort of children. Interestingly, high exposure to NO₂ the week after the onset of the viral infection was not associated with changes in lower respiratory tract symptoms or peak expiratory flow measurements [22]. These data suggest that exposure to NO₂ had a priming effect on the symptoms associated with the subsequent naturally acquired viral infection in children with asthma. Our data presented here show similar results in that exposure to DEP or infection with influenza alone did not increase markers of allergic inflammation. Only animals that were exposed to DEP prior to infection with influenza showed significant changes in the number of BALF/lung eosinophils, CCL11, CCR3, or TH2 cytokines, suggesting that exposure to DEP primed the animals for virus-induced exacerbation of allergic inflammation.

We found a trend towards increased viral titers 18 hours post viral inoculation in the DEP-treated groups, at the
time we observed enhanced allergic inflammation in the lung. These findings are consistent with previous studies which have demonstrated at later time points that repeated exposures to DE, prior to infection with influenza, increase markers of viral replication in epithelial cells in vitro and in mice in vivo [20,21]. A potential mechanism for this enhanced viral replication following DE exposure is a reduction in the expression of important antimicrobial defense molecules, a recent observation by our group [21,26]. The potential clinical significance of these findings is highlighted by human studies showing a relationship between TH1/2 immune responses, viral load, and symptom severity in asthmatic subjects experimentally infected with RV [27].

Whether virus-induced exacerbation of asthma is associated with an increase in total viral load or a shift in the location of the infection remains to be determined. For example, a recent study demonstrated that asthmatics can harbor RV infection in the lower airways and that this shift in location of the RV infection is associated with virus-induced exacerbation of asthma [28]. In addition, another study demonstrated that the severity of lower respiratory tract symptoms in subjects diagnosed with a respiratory virus infection was greater in asthmatics, but that these effects were not related to the viral load in the upper respiratory tract [29]. Thus, we cannot rule out the possibility that exposure to DE can modify the distribution of the viral infection in the lower respiratory tract, and potentiate allergic inflammation by that mechanism.

Recruitment of eosinophils into the lung is regulated by the expression of specific chemokines such as the eotaxins (CCL11 and CCL24 in mice), which are selective agonists for the C-C chemokine receptor 3 (CCR3). Considering the significant influx of tissue and BALF eosinophils, it is likely that the enhanced CCR3 we observed in our study are derived from the increased number of CCR3-expressing cells. In addition to observing increased numbers of CCR3-expressing eosinophils, our data also showed that exposure to DEP prior to infection with influenza increases the expression of CCL11. Cellular sources for CCL11 include endothelial cells, mast cells, fibroblasts, airway epithelial cells, smooth muscle cells, eosinophils, and various other cell types. Its expression can be activated by a number of inflammatory cytokines, such as IL-1, TNF and IFN [30]. In addition, exposure to DE alone has been shown to increase the expression of eotaxin in airway epithelial cells [31] and instillation with DEP alone or in combination with OVA increased lung eotaxin levels [32]. However, our data suggest that in mice sensitized and challenged with OVA, a single exposure to DEP alone is not sufficient to significantly enhance the expression of eotaxin in the lung. Similarly, only mice exposed to DEP prior to infection with influenza showed significant increases in BALF and tissue eosinophils. Potential reasons for these differences include the fact that we used

| Table 2: Lung homogenate cytokine levels |
|----------------------------------------|
|                                 | IL-10 | IL-1α | MCP-1 | RANTES |
| Sal/Sal (n = 11) | 0.59 ± 0.15 | 1.57 ± 0.26 | 6.83 ± 1.41 | 9.84 ± 1.80 |
| DEP/Sal (n = 8)  | 0.72 ± 0.09 | 2.57 ± 0.60 | 8.64 ± 1.71 | 8.44 ± 1.86 |
| Sal/Flu (n = 11) | 0.66 ± 0.11 | 2.46 ± 0.37 | 8.80 ± 1.99 | 8.83 ± 1.25 |
| DEP/Flu (n = 9)  | 0.73 ± 0.12 | 3.99 ± 0.96* | 9.08 ± 1.58 | 10.70 ± 1.42 |

Cytokine levels in whole lung homogenates. Whole lung homogenates were analyzed for IL-10, IL-1α, MCP-1, and RANTES. Cytokines levels were normalized to lung tissue weight and expressed as pg/ml/mg tissue. *significantly different from Sal/Sal control; p < 0.05.
a single instillation of DEP shortly after the last OVA challenge rather than repeated instillations of DEP in combination with OVA challenge [32]. In addition, the type of DEP and its chemical characteristics can significantly affect its ability to potentiate allergic inflammation in OVA-sensitized mice as has recently been demonstrated [33]. The authors of that study demonstrated that BALB/c mice instilled with three chemically distinct DEP samples during the OVA sensitization phase responded differently with regards to potentiation of allergic inflammation. Furthermore, we used C57BL/6 mice in the studies presented here, which are less responsive to OVA-induced allergic airway inflammation as compared to BALB/c mice [34]. Similarly, DEP-induced exacerbation of allergic inflammation differs among mouse strains [35]. Thus, in addition to timing of the DEP exposure in relation to sensitization and/or challenge with OVA, chemical composition of the DEP sample as well as mouse strain are important determinants with regards to DEP-induced enhancement of allergic inflammation.

A number of studies have shown that IL-1 may play a central role during allergic inflammation. For example, administration of an IL-1 receptor antagonist (IL-1ra) decreased lung eotaxin levels and infiltration of eosinophils in OVA-sensitized mice [36]. The authors suggested that IL-1 is necessary for allergen-specific TH2 cell activation and allergic inflammation and that administration of recombinant IL-1ra decreases allergic inflammation either directly by inhibiting the pro-inflammatory activity of IL-1 or indirectly by inhibiting the expression of IL-5 and eotaxin [36]. Our data indicate that in mice exposed to DEP prior to infection with influenza, BALF IL-1 levels were significantly enhanced as compared to the other groups. Thus, it is conceivable that in animals that were exposed to DEP prior to infection with influenza, an increase in IL-1 sets off a cascade culminating in the enhanced expression of TH2 cytokines and accumulation of eosinophils in the lung.

### Table 3: OVA-specific immunoglobulin levels

|          | IgG2c         | IgE           | IgG1         |
|----------|---------------|---------------|--------------|
| Sal/Sal  | 354.4 ± 108.4 | 42973 ± 8680  | 384.5 ± 58.54|
| (n = 10) | (n = 11)      | (n = 10)      |              |
| DEP/Sal  | 199.3 ± 51.38 | 72669 ± 13391 | 428.1 ± 30.89|
| (n = 9)  | (n = 8)       | (n = 9)       |              |
| Sal/Flu  | 128.0 ± 38.94 | 79598 ± 13747 | 488.6 ± 41.34|
| (n = 9)  | (n = 10)      | (n = 11)      |              |
| DEP/Flu  | 355.2 ± 131.3 | 78654 ± 14977 | 434.1 ± 47.33|
| (n = 10) | (n = 10)      | (n = 10)      |              |

Figures 6
Exposure to DEP prior to infection with influenza increases markers of Th2-type immune response. A.) Cell-free BALF was analyzed for IL-13 levels. B.) Whole lung homogenates were analyzed for IL-4 levels. C.) Total RNA isolated from whole lung was analyzed for IL-4rα mRNA levels and normalized to β-actin mRNA levels. *significantly different from Sal/Sal control; p < 0.05.
In conclusion, to our knowledge this is the first study providing direct experimental evidence that exposure to air pollutants prior to infection with respiratory virus significantly exacerbates allergic airway inflammation. Since concurrent exposure to air pollutants and infection with respiratory viruses is likely, these findings could be of significant public health implication. This notion is supported by epidemiological studies demonstrating that exposure to oxidant air pollutants prior to the onset of a respiratory virus infection do in fact enhance exacerbation of asthma in a cohort of children [22]. Future studies are necessary to further depict the molecular mechanisms by which exposure to oxidant air pollutants, potentiate virus-induced exacerbation of allergic inflammation.

**Materials and methods**

**Animals**

Similar to our previous studies using influenza virus infection [37,38] or an ovalbumin sensitization model [39], male C57BL/6 mice 6–8 weeks old were used throughout the study. All experimental procedures were approved by the University of North Carolina IACUC. Based on our previous studies [39] and as outlined in Fig. 1, mice were sensitized on days 1 and 2 by i.p. injection of 100 μl of 1% ovalbumin/alum solution. On days 14, 15, and 16 mice were challenged with aerosolized ovalbumin (1% wt/v) for 30 min/day. A minimum of 5 animals were used for each endpoint.

**Oropharyngeal Aspiration of Diesel Exhaust Particles**

Diesel exhaust particles (DEP) were kindly provided by Dr. M. Ian Gilmour and collected as described before [40]. Briefly, a 30-kW (40 hp) four-cylinder Deutz BF4M1008 diesel engine connected to a 22.3-kW Saylor Bell air compressor to provide a load was used to generate the DEP. The engine and compressor were operated at steady state to produce 0.8 m³/min of compressed air at 400 kPa. This translates to ~20% of the engine's full-load rating. Emissions from the engine were diluted with filtered air (3:1) to near ambient temperatures (~35°C) and directed to a small baghouse (Dusyex model T6-3.5-9 150 ACFM pyramidal baghouse using a polyester felt bag). Gram quantities of DEP were collected from the baghouse using reverse air pulsing. Once collected, the DEP samples were stored in sealed containers in a refrigerator (~4°C). For the exposure, DEP was suspended in sterile HBSS and sonicated prior to oropharyngeal aspiration of DEP as described before [41]. Briefly, on day 16 approximately 4 hours after the last OVA challenge, animals were anesthetized using vaporized halothane and suspended on their incisors. The tongue was distended and a bolus of either 50 μl HBSS vehicle or 25 μg DEP in 50 μl HBSS was injected onto the oropharynx. Involuntary aspiration was induced by blocking the animal’s nares.

**Influenza virus infection**

Influenza A/PR/8 (H1N1) was propagated in 10-day-old embryonated hens' eggs. The virus was collected in the allantoic fluid and titered by hemagglutination as described by us before [37,38]. For virus inoculation, mice were anesthetized with an intraperitoneal injection of ketamine (0.022 mg) and xylazine (0.0156 mg) on day 17 (approximately 20 hours after instillation with DEP or HBSS vehicle) and instilled intranasally with 500 pfu of influenza virus in 0.05 mL of PBS.

**Bronchoalveolar Lavage**

Approximately 18 h post infection (on day 18), mice from each treatment group were euthanized with sodium pentobarbital and the trachea was exposed, cannulated, and secured with suture thread. The left mainstem bronchus was isolated, clamped with alligator clips after the trachea was cannulated. The right lungs lobes were lavaged 3 times with three volumes of warmed Hanks balanced salt solution (HBSS) (Invitrogen, Grand Island, NY) (35 ml/kg). The resulting lavage was centrifuged (500 × g, 5 min, 4°C) and cell-free lavage fluid was stored at -80°C for cytokine measurement. The pelleted cells were resuspended in 1 ml of RPMI 1640 (Gibco, Carlsbad, CA) containing 2.5% fetal bovine serum (FBS; Gibco, Carlsbad, CA). Total cell counts in the lavage fluid of each mouse were obtained using a hemacytometer. Each sample (100 and 300 μl) was centrifuged in duplicate onto slides using a Cytospin (Shandon, Pittsburgh, PA) and subsequently stained with Diff Quik solution (American...
Scientific, McGraw Park, PA) for cell differentiation determination, with at least 200 cells counted from each slide. The left lobe was then removed for RNA, protein isolation, or immunohistochemistry.

**Differential Peripheral Blood Leukocyte Count**

Blood was collected by cardiac puncture and stored in EDTA-tubes. Each sample was centrifuged onto slides using a Cytospin (Shandon, Pittsburgh, PA) and subsequently stained with Diff Quik solution (American Scientific, McGraw Park, PA) for cell differentiation determination, with at least 200 cells counted from each slide.

**Cytokine Measurements**

IL-13 concentrations in cell-free bronchoalveolar lavage (BAL) as well as IL-4, IL-10, IL-1α, MCP-1, and RANTES in lung homogenates were measured using a Cytokine Fluorescent Bead Immunoassay Assay Kits (Beadlyte®; Millipore, Billerica, MA). Lung homogenates were prepared by using FastPrep® Lysing Matrix tubes (Millipore). Briefly, snap-frozen lung tissue was homogenized in HBSS using the Lysing Matrix D tubes and the Bio101® FastPrep® system (MP Biomedicals, Solon, OH). Homogenates were centrifuged to clear cellular debris and the cytokine levels were normalized to mg tissue used in the homogenate.

**Real Time PCR**

Total RNA was extracted from snap-frozen lung tissue with TRIzol (Invitrogen, Grand Island, NY) as per the supplier’s instructions. First strand cDNA synthesis and real-time RT-PCR were performed as previously described [20] using commercially available primers and probes (Applied Biosystems, Foster City, CA).

**Histology**

Lung tissue samples were fixed in 4% paraformaldehyde and embedded in paraffin. Five μm thick sections were placed on Superfrost/plus slides (Fisher Scientific) and stained using hematoxylin and eosin (H&E; Richard Allan, Richland, MI) to assess inflammatory infiltrates. To identify tissue eosinophils, sections were stained using a Carbol Chromotrope stain, using Chromotrope 2R (Sigma) dissolved in Phenol. Sections were counterstained using hematoxylin and the slides were evaluated under light microscopy. Five to ten fields of at least 3 animals per experimental group were evaluated for the H&E stain. Tissue eosinophils were enumerated by counting eosinophils surrounding blood vessel and Airways using 40× and 100× magnification. Similar to previous reports [42], at least 5 visual fields with blood vessel (diameter 10–50 μm) or bronchioles (diameter 150–200 μm) per animal were evaluated for n = 5 animals per experimental group.

**Quantitation of Viral Titers**

Lung viral titers were determined by a modified tissue culture infections dose 50 (TCID<sub>50</sub>) using hemagglutination as an endpoint, as previously described [43]. Briefly, snap frozen lung tissue was weighed and homogenized using homogenized in minimal essential medium using the Lysing Matrix D tubes and the Bio101® FastPrep® system (MP Biomedicals, Solon, OH). Samples were centrifuged at 9000 x g for 20 min and the supernatant was serially diluted starting at 1:5 in MEM containing 20 mg/L trypsin. Each diluted supernatant (100 μL) was added, in 6 replicates, to 80% confluent MDCK cells and incubated at 37°C for 72 h. A 0.5% suspension of human O RBC (50 μL) was added to each well and incubated at room temperature for 2 h. Viral titer was expressed as the reciprocal of the highest dilution at which the RBC agglutinated. This value was then normalized to mg tissue of the sample.

**Analysis of OVA-specific immunoglobulin levels**

High binding microplates were coated with 100 μl ovalbumin (Sigma) in PBS at 1 mg/ml (IgG1 and IgG2c assays) or 20 mg/ml (IgE assay) at 37°C for 2 hours, followed by incubation with 200 μl/well blocking buffer (1% BSA in PBS) for 1 hour at room temperature. Standard curves for IgG1 and IgG2c were prepared by diluting pooled sera that had previously tested as highly concentrated in OVA-specific IgG1 or IgG2c. In the IgE assay, mouse anti-ovalbumin IgE (AbD Serotec, Raleigh, NC) was used as a standard. One-hundred microliters of each standard or sample dilution was applied to the wells in triplicate and incubated overnight at 4°C and 100 μl of biotinylated anti-Mouse IgG1 (BD Biosciences; 2 ug/ml), biotinylated anti-Mouse IgG2c (Southern Biotechnology; 1:5000), or biotinylated anti-Mouse IgE (BD Biosciences; 4:1000) was added to each well and incubated at room temperature for 30 minutes. Streptavidin-HRP (BD Biosciences; 1:1000), was applied to each well and incubated 30 minutes at room temperature, followed by the addition of TMB substrate (eBioscience). Absorbances were read at 450 nm and concentrations for IgG1 and IgG2c are expressed as arbitrary units.

**Statistical Analysis**

Data are shown as mean ± S.E.M. At least 5 animals per experimental group were analyzed, although many endpoints were examined in >5 animals. Data were analyzed using a one-way ANOVA followed by Bonferroni post-hoc test to determine significant differences among the individual groups. A value of p < 0.05 was considered statistically significant.

**Abbreviations**

OVA: ovalbumin; DEP: diesel exhaust particles; Flu: influenza; BALF: bronchoalveolar lavage fluid; Sal: Saline; Ig:
Immunoglobulin; NO₂: nitrogen dioxide; IL: interleukin; TNF: tumor necrosis factor; CCL: chemokine (C-C motif) ligand; CCR: C-C chemokine receptor

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
IJ conceived of the study, participated in its design and coordination, evaluated the overall study, and drafted the manuscript; PAS carried out the viral infections and assisted in the tissue analysis; WZ carried out the cytokine analysis; LEB carried out the histology analysis; KDC conducted and analyzed the OVA-specific immunoglobulin assays; XH participated in the animal exposures and tissue collection; SLT participated in the design of the study, coordinated the animal exposures, and helped in the tissue collection and drafting of the manuscript. All authors read and approved the final manuscript.

Acknowledgements
We thank Dr MJ. Gilmour for providing the diesel exhaust particles and helpful discussions regarding the experimental design. The project described was in part supported by grant number ES013611 from the National Institute for Environmental Health Sciences (NIEHS), NIH, and a grant from the Environmental Protection Agency (CR829522) (all ‘I’s). Its content are solely the responsibility of the authors and do not necessarily represent the official views of the NIEHS, NIH. Although the research described in this article has been funded wholly or in part by the United States Environmental Protection Agency through cooperative agreement CR829522 with the Center for Environmental Medicine, Asthma, and Lung Biology, it has not been subjected to the Agency’s required peer and policy review, and therefore does not necessarily reflect the views of the Agency and no official endorsement should be inferred. Mention of trade names or commercial products does not constitute endorsement or recommendation and no official endorsement should be inferred. 

References
1. Misso NL, Thompson PJ: Oxidative stress and antioxidant deficiencies in asthma: potential modification by diet. Redox Rep 2005, 10(3):247-255.
2. Schwartz J, Slater D, Larson TV, Pierson WE, Koenig JQ: Particulate air pollution and hospital emergency room visits for asthma in Seattle. Am Rev Respir Dis 1993, 147(4):826-831.
3. Pope CA: Epidemiology of fine particulate air pollution and human health: biological mechanisms and who’s at risk? Environ Health Perspect 2000, 108(Suppl 4):713-723.
4. Diaz-Sanchez D: The role of diesel exhaust particles and their associated polyaromatic hydrocarbons in the induction of allergic airway disease. Allergy 1997, 52(38 Suppl):52-56. discussion 57-58.
5. Takano H, Yoshikawa T, Ichinose T, Miyabara Y, Imaoka K, Sagai M: Diesel exhaust particles enhance antigen-induced airway inflammation and local cytokine expression in mice. Am J Respir Crit Care Med 1997, 156(1):26-42.
6. Fedulov AV, Leme A, Yang Z, Dahl M, Lim R, Mariani TJ, Kobzik L: Pulmonary exposure to particles during pregnancy causes increased neonatal asthma susceptibility. Am J Respir Cell Mol Biol 2008, 38(1):57-67.
7. Hao M, Comier S, Wang M, Lee JJ, Nel A: Diesel exhaust particles exert acute effects on airway inflammation and function in murine allergen provocation models. J Allergy Clin Immunol 2003, 112(5):905-914.
8. Farraj AK, Haykal-Coates N, Ledbetter AD, Evansky PA, Gavetz SH: Neurotrophin mediation of allergic airways responses to inhaled diesel particles in mice. Toxicol Sci 2006, 94(1):183-192.
9. Takano H, Ichinose T, Miyabara Y, Shibuya T, Lim HB, Yoshikawa T, Sagai M: Inhalation of diesel exhaust enhances allergen-related eosinophil recruitment and airway hyperresponsiveness in mice. Toxicol Appl Pharmacol 1998, 150(2):328-337.
10. Holgate ST, Sandstrom T, Frew AJ, Steenfors N, Nordenhall C, Salvi S, Blomberg A, Helleday R, Soderberg M: Health effects of acute exposure to air pollution. Part I: Healthy and asthma subjects exposed to diesel exhaust. Res Rep Health Eff Inst 2003:1-30. discussion S1-67.
11. Manessier E, Nieves A, Vervloet D, Magnan A: Diesel exhaust particulate enhance T-cell activation in severe asthmatics. Allergy 2006, 61(5):581-588.
12. Bayram H, Devalia JL, Khair OA, Abdelaziz MM, Sasford RJ, Sagai M, Davies RJ: Comparison of ciliary activity and inflammatory mediator release from bronchial epithelial cells of nonatopic nonasthmatic subjects and atopic asthmatic patients and the effect of diesel exhaust particles in vitro. J Allergy Clin Immunol 1998, 102(5):771-782.
13. Devalia JL, Bayram H, Abdelaziz MM, Sasford RJ, Davies RJ: Differences between cytokine release from bronchial epithelial cells of asthmatic patients and non-asthmatic subjects: effect of exposure to diesel exhaust particles. Int Arch Allergy Immunol 1999, 118(2-4):437-439.
14. Tan WC. Viruses in asthma exacerbations. Curr Opin Pulm Med 2005, 11(1):21-26.
15. Lemanske RF: Viruses and asthma: Inception, exacerbation, and possible prevention. J Pediatr 2003, 142(2 Suppl):S3-7. discussion S7-8.
16. Johnston SL: Overview of virus-induced airway disease. Proc Am Thorac Soc 2005, 2(2):150-156.
17. Teichtahl H, Buckmaster N, Pertnikovs E: The incidence of respiratory tract infection in adults requiring hospitalization for asthma. Chest 1997, 112(3):591-596.
18. Gern JE, Lemanske RF: Infectious triggers of pediatric asthma. Pediatr Clin North Am 2003, 50(3):535-575.
19. Marsland BJ, Scanga CB, Kopf M, Le Gros G: Allergic airway inflammation is exacerbated during acute influenza infection and correlates with increased allergen presentation and recruitment of allergen-specific T-helper type 2 cells. Clin Exp Allergy 2004, 34(8):1299-1306.
20. Jaspers I, Ciencewicki JM, Zhang W, Brighton LE, Carson JL, Beck MA, Madden MC: Diesel exhaust enhances influenza virus infections in respiratory epithelial cells. Toxicol Sci 2005, 85(2):990-1002.
21. Ciencewicki J, Gowdy K, Kranzt QT, Link WP, Brighton L, Gilmour MI, Jaspers I: Diesel exhaust enhanced susceptibility to influenza infection is associated with decreased surfactant protein expression. Inhal Toxicol 2007, 19(14):1121-1133.
22. Chauhan AJ, Inskip HM, Linaker CH, Smith S, Schreiber J, Johnston SL, Holgate ST: Personal exposure to nitrogen dioxide (NO2) and the severity of virus-induced asthma in children. Lancet 2003, 361(9373):1939-1944.
23. Rothenberg ME: Eotaxin. An essential mediator of eosinophil trafficking into mucosal tissues. Am J Respir Cell Mol Biol 1999, 21(3):291-295.
24. Ichinose T, Takano H, Miyabara Y, Sadakaneo K, Sagai M, Shimamoto T: Enhancement of antigen-induced eosinophilic inflammation in the airways of mast-cell deficient mice by diesel exhaust particles. Toxicology 2002, 183(3):293-301.
25. Miyabara Y, Ichinose T, Takano H, Lim HB, Sagai M: Effects of diesel exhaust on allergic airway inflammation in mice. J Allergy Clin Immunol 1998, 102(5):805-812.
26. Gowdy K, Kranzt QT, Dawe R, Link WP, Jaspers I, Gilmour MI: Modulation of pulmonary inflammatory responses and antimicrobial defenses in mice exposed to diesel exhaust. Toxicol Appl Pharmacol 2008, 229(3):310-319.
27. Message SD, Laza-Stanca V, Mallia P, Parker HL, Zhu J, Kebadze T, Contoli M, Sanderson G, Kon OM, Papi A, et al: Rhinovirus-induced lower respiratory illness is increased in asthma and related to virus load and Th1/2 cytokine and IL-10 production. Proc Natl Acad Sci USA 2008, 105(36):13562-13567.
28. Wos M, Sanak M, Soja J, Olechnowicz H, Busse WW, Szczeklik A: The presence of rhinovirus in lower airways of patients with
bronchial asthma. Am J Respir Crit Care Med 2008, 177(10):1082-1089.

29. van Elden LJ, Sacha AP, van Loon AM, Haarman M, Vijver DA van de, Kimman TG, Zuidhoff P, Schipper PJ, Verheij TJ, Nijhuis M: Enhanced severity of virus associated lower respiratory tract disease in asthma patients may not be associated with delayed viral clearance and increased viral load in the upper respiratory tract. J Clin Virol 2008, 41(2):116-121.

30. Foster PS, Mould AW, Yang M, Mackenzie J, Mattes J, Hogan SP, Mahalingam S, Mckenzie AN, Rothenberg ME, Young IG, et al: Elemental signals regulating eosinophil accumulation in the lung. Immunol Rev 2001, 179:173-181.

31. Takizawa H, Abe S, Okazaki H, Kobayashi T, Sugawara I, Saito Y, Ohtoshi T, Kawasaki S, Desaki M, Nakahara K, et al: Diesel exhaust particles upregulate eotaxin gene expression in human bronchial epithelial cells via nuclear factor-kappa B-dependent pathway. Am J Physiol Lung Cell Mol Physiol 2003, 284(6):L1055-1062.

32. Takano H, Yanagisawa R, Inoue K: Components of diesel exhaust particles diversely enhance a variety of respiratory diseases related to infection or allergy: extracted organic chemicals and the residual particles after extraction differently affect respiratory diseases. J Clin Biochem Nutr 2007, 40(2):101-107.

33. Stevens T, Cho SH, Linak WP, Gilmour MI: Differential potentiation of allergic lung disease in mice exposed to chemically distinct diesel samples. Toxicol Sci 2009, 107(2):522-534.

34. Zhu W, Gilmour MI: Comparison of allergic lung disease in three mouse strains after systemic or mucosal sensitization with ovalbumin antigen. Immunogenetics 2009, 61(3):199-207.

35. Ichinose T, Takano H, Miyabara Y, Yanagisawa R, Sagai M: Murine strain differences in allergic airway inflammation and immunoglobulin production by a combination of antigen and diesel exhaust particles. Toxicology 1997, 121(3-4):183-192.

36. Wang CC, Fu CL, Yang YH, Lo YC, Wang LC, Chiang YH, Chang DM, Chiang BL: Adenovirus expressing interleukin-1 receptor antagonist alleviates allergic airway inflammation in a murine model of asthma. Gene Ther 2006, 13(19):1414-1421.

37. Smith AG, Sheridan PA, Harp JB, Beck MA: Diet-induced obese mice have increased mortality and altered immune responses when infected with influenza virus. J Nutr 2007, 137(5):1236-1243.

38. Smith AG, Sheridan PA, Tseng RJ, Sheridan JF, Beck MA: Selective impairment in dendritic cell function and altered antigen-specific CD8+ T-cell responses in diet-induced obese mice infected with influenza virus. Immunology 2009, 126(2):268-279.

39. Tilley SL, Jaradat M, Stapleton C, Dixon D, Hua X, Erikson CJ, McCaskill JG, Chason KD, Liao G, Jania L, et al: Retinoid-related orphan receptor gamma controls immunoglobulin production and Th1/Th2 cytokine balance in the adaptive immune response to allergen. J Immunol 2007, 178(5):3208-3218.

40. Cao D, Tal TL, Graves LM, Gilmour I, Linak W, Reed W, Bromberg PA, Samet JM: Diesel exhaust particulate-induced activation of Stat3 requires activities of EGFR and Src in airway epithelial cells. Am J Physiol Lung Cell Mol Physiol 2007, 292(2):L422-429.

41. Singh P, DeMarini DM, Dick CA, Tabor DG, Ryan JV, Linak WP, Kobayashi T, Gilmour MI: Sample characterization of automobile and forklift diesel exhaust particles and comparative pulmonary toxicity in mice. Environ Health Perspect 2004, 112(8):820-825.

42. Lim DH, Cho JY, Song DJ, Lee SY, Miller M, Broide DH: PI3K gamma-deficient mice have reduced levels of allergen-induced eosinophilic inflammation and airway remodeling. Am J Physiol Lung Cell Mol Physiol 2009, 296(2):L210-219.

43. Farag-Mahmod FI, Wyde PR, Rosborough JP, Six HR: Immunogenicity and efficacy of orally administered inactivated influenza virus vaccine in mice. Vaccine 1988, 6(3):262-268.